[go: up one dir, main page]

ZA200207273B - Indol-3-yl-derivatives and their use as integrin inhibitors. - Google Patents

Indol-3-yl-derivatives and their use as integrin inhibitors. Download PDF

Info

Publication number
ZA200207273B
ZA200207273B ZA200207273A ZA200207273A ZA200207273B ZA 200207273 B ZA200207273 B ZA 200207273B ZA 200207273 A ZA200207273 A ZA 200207273A ZA 200207273 A ZA200207273 A ZA 200207273A ZA 200207273 B ZA200207273 B ZA 200207273B
Authority
ZA
South Africa
Prior art keywords
formula
het
pyridin
propionic acid
ylamino
Prior art date
Application number
ZA200207273A
Other languages
English (en)
Inventor
Simon Goodman
Matthias Wiesner
Rudolf Gottschlich
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of ZA200207273B publication Critical patent/ZA200207273B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
ZA200207273A 2000-02-11 2002-09-10 Indol-3-yl-derivatives and their use as integrin inhibitors. ZA200207273B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10006139A DE10006139A1 (de) 2000-02-11 2000-02-11 Indol-3-yl-Derivate

Publications (1)

Publication Number Publication Date
ZA200207273B true ZA200207273B (en) 2003-12-10

Family

ID=7630611

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200207273A ZA200207273B (en) 2000-02-11 2002-09-10 Indol-3-yl-derivatives and their use as integrin inhibitors.

Country Status (28)

Country Link
US (1) US6743810B2 (pt)
EP (1) EP1254133B9 (pt)
JP (1) JP4938194B2 (pt)
KR (1) KR20020073585A (pt)
CN (1) CN1214026C (pt)
AR (1) AR027398A1 (pt)
AT (1) ATE293620T1 (pt)
AU (2) AU3166401A (pt)
BR (1) BR0108154A (pt)
CA (1) CA2399813C (pt)
CO (1) CO5261548A1 (pt)
CZ (1) CZ20022616A3 (pt)
DE (2) DE10006139A1 (pt)
EC (1) ECSP013923A (pt)
ES (1) ES2240400T3 (pt)
HK (1) HK1051863A1 (pt)
HU (1) HUP0302671A2 (pt)
IL (1) IL151154A0 (pt)
MX (1) MXPA02007732A (pt)
NO (1) NO20023770D0 (pt)
NZ (1) NZ521260A (pt)
PE (1) PE20011125A1 (pt)
PL (1) PL356427A1 (pt)
PT (1) PT1254133E (pt)
RU (1) RU2257380C2 (pt)
SK (1) SK11152002A3 (pt)
WO (1) WO2001058893A2 (pt)
ZA (1) ZA200207273B (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040063790A1 (en) * 1996-05-31 2004-04-01 The Scripps Research Institute Methods for inhibition of angiogenesis
US20040138284A1 (en) * 2000-02-11 2004-07-15 Matthias Wiesner Indol-3-yl derivatives
JP2004521079A (ja) * 2000-08-29 2004-07-15 ファルマシア・コーポレーション アルファーｖベータ３アンタゴニストとして有用な二環式環系を含有する化合物
ATE415163T1 (de) * 2000-11-01 2008-12-15 Merck Patent Gmbh Verfahren und zusammensetzungen zur behandlung von augenerkrankungen
GB0028367D0 (en) * 2000-11-21 2001-01-03 Celltech Chiroscience Ltd Chemical compounds
MXPA03006772A (es) * 2001-01-29 2004-10-15 Dimensional Pharm Inc Indoles sustituidos y su uso como antogonistas de integrina.
US6872730B2 (en) 2001-04-27 2005-03-29 3-Dimensional Pharmaceuticals, Inc. Substituted benzofurans and benzothiophenes, methods of making and methods of use as integrin antagonists
KR20040028966A (ko) 2001-08-01 2004-04-03 메르크 파텐트 게엠베하 안구 질환 치료용 인테그린 억제제
MXPA04007770A (es) * 2002-02-14 2004-10-15 Merck Patent Gmbh Metodos y composiciones para tratamiento de enfermedades de los ojos.
US20070208026A1 (en) * 2003-04-07 2007-09-06 Liu Kevin N-Containing Heteroaromatic Compounds As Modulators Of Ppars And Methods Of Treating Metabolic Disorders
CA2523245C (en) * 2003-04-28 2012-03-06 Bayer Pharmaceuticals Corporation Indole acetic acid derivatives and their use as pharmaceutical agents
US7211588B2 (en) 2003-07-25 2007-05-01 Zentaris Gmbh N-substituted indolyl-3-glyoxylamides, their use as medicaments and process for their preparation
DE10337863A1 (de) * 2003-08-18 2005-03-17 Merck Patent Gmbh Verwendung von Chromen-4-on-Derivaten
WO2005039547A1 (en) * 2003-10-01 2005-05-06 Merck Patent Gmbh Alfavbeta3 and alfavbeta6 integrin antagonists as antifibrotic agents
JP2007536344A (ja) * 2004-05-04 2007-12-13 ノボ　ノルディスク　アクティーゼルスカブ 新規のインドール誘導体
WO2006053342A2 (en) * 2004-11-12 2006-05-18 Osi Pharmaceuticals, Inc. Integrin antagonists useful as anticancer agents
WO2007024294A2 (en) * 2005-05-03 2007-03-01 Cgi Pharmaceuticals, Inc. Certain substituted ureas, as modulators of kinase activity
CN102335168B (zh) * 2011-10-25 2014-04-02 合肥博太医药生物技术发展有限公司 吲哚-3-甲醇、二吲哚甲烷及其衍生物在制备治疗骨质疏松药物中的应用
AR094812A1 (es) * 2013-02-20 2015-08-26 Eisai R&D Man Co Ltd Derivado de piridina monocíclico como inhibidor del fgfr
CA2956270C (en) 2014-08-18 2022-08-09 Eisai R&D Management Co., Ltd. Salt of monocyclic pyridine derivative and crystal thereof
US11219619B2 (en) 2018-03-28 2022-01-11 Eisai R&D Management Co., Ltd. Therapeutic agent for hepatocellular carcinoma

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT290523B (de) * 1962-01-05 1971-06-11 Merck & Co Inc Verfahren zur Herstellung neuer α-(3-Indolyl)-carbonsäuren
GB1148908A (en) * 1965-04-19 1969-04-16 Sumitomo Chemical Co Indole derivatives and processes for making them
US4824850A (en) * 1982-05-18 1989-04-25 University Of Florida Brain-specific drug delivery
US4983615A (en) * 1989-06-28 1991-01-08 Hoechst-Roussel Pharmaceuticals Inc. Heteroarylamino- and heteroaryloxypyridinamine compounds which are useful in treating skin disorders
IT1244548B (it) * 1991-02-06 1994-07-15 Poli Ind Chimica Spa Derivati della 5-oxo-l-prolina e loro applicazioni farmaceutiche
GB9225141D0 (en) 1992-12-01 1993-01-20 Smithkline Beecham Corp Chemical compounds
EP0901373B1 (en) * 1996-04-10 2002-11-06 Merck & Co., Inc. Alpha v Beta 3 ANTAGONISTS
AU4091697A (en) * 1996-08-27 1998-03-19 American Home Products Corporation 4-aminoethoxy indoles as dopamin d2 agonists and as 5ht1a ligands
WO1999033798A1 (fr) * 1997-12-25 1999-07-08 Yamanouchi Pharmaceutical Co., Ltd. Derives heterocycliques azotes
WO1999042102A1 (en) * 1998-02-23 1999-08-26 South Alabama Medical Science Foundation Indole-3-propionic acids, salts and esters thereof used as medicaments
GEP20032920B (en) * 1998-02-25 2003-03-25 Genetics Inst Inhibitors of Phospholipase Enzymes
PT1068184E (pt) * 1998-04-08 2002-12-31 Wyeth Corp Derivados n-ariloxietilamina para o tratamento de depressao
CA2327359A1 (en) * 1998-04-08 1999-10-14 Wyeth N-aryloxyethyl-indoly-alkylamines for the treatment of depression (5-ht1a receptor active agents)
JP4425699B2 (ja) * 2004-05-17 2010-03-03 川崎重工業株式会社 小型滑走艇

Also Published As

Publication number Publication date
CA2399813A1 (en) 2001-08-16
CA2399813C (en) 2010-03-09
RU2257380C2 (ru) 2005-07-27
ATE293620T1 (de) 2005-05-15
ES2240400T3 (es) 2005-10-16
DE50105955D1 (de) 2005-05-25
NZ521260A (en) 2004-02-27
PE20011125A1 (es) 2001-11-07
PT1254133E (pt) 2005-09-30
BR0108154A (pt) 2003-01-21
AU2001231664B2 (en) 2006-02-23
NO20023770L (no) 2002-08-09
EP1254133B9 (de) 2005-09-07
MXPA02007732A (es) 2002-10-11
AU2001231664C1 (en) 2006-10-05
CN1214026C (zh) 2005-08-10
CZ20022616A3 (cs) 2002-10-16
AR027398A1 (es) 2003-03-26
US6743810B2 (en) 2004-06-01
RU2002123332A (ru) 2004-01-10
HK1051863A1 (en) 2003-08-22
EP1254133B1 (de) 2005-04-20
PL356427A1 (en) 2004-06-28
DE10006139A1 (de) 2001-08-16
HUP0302671A2 (hu) 2003-12-29
US20030045728A1 (en) 2003-03-06
AU3166401A (en) 2001-08-20
CN1398264A (zh) 2003-02-19
SK11152002A3 (sk) 2003-01-09
WO2001058893A2 (de) 2001-08-16
NO20023770D0 (no) 2002-08-09
JP4938194B2 (ja) 2012-05-23
EP1254133A2 (de) 2002-11-06
JP2003530319A (ja) 2003-10-14
IL151154A0 (en) 2003-04-10
WO2001058893A3 (de) 2002-04-18
ECSP013923A (es) 2002-09-27
CO5261548A1 (es) 2003-03-31
KR20020073585A (ko) 2002-09-27

Similar Documents

Publication Publication Date Title
ZA200207273B (en) Indol-3-yl-derivatives and their use as integrin inhibitors.
CA2259224A1 (en) Phenylalamine derivatives as integrin inhibitors
US6559144B2 (en) Bicyclic amino acids
RU2187506C2 (ru) Бициклические ароматические аминокислоты
ZA200308024B (en) Inhibitors of integrin alphavbeta6.
RU2234505C2 (ru) Производные хроменона и хроманона в качестве ингибиторов интегринов
CA2431974C (en) Urea and urethane derivatives as integrin inhibitors
JP2005519929A (ja) インテグリンαｖβ６の阻害剤
US6649613B1 (en) Diacylhydrazine derivatives
CZ20033000A3 (cs) Inhibitory integrinů a(v)B6
US20040138284A1 (en) Indol-3-yl derivatives
JP2003507458A (ja) 新規なインテグリンαｖβ３阻害剤
UA55439C2 (uk) Похідні циклопептидів, спосіб їх одержання, фармацевтична композиція, спосіб її одержання
ZA200302253B (en) Biphenyl derivatives and the use thereof as integrin inhibitors.
JP2002542231A (ja) 血栓症、骨粗鬆症、動脈硬化症を処置するためのジベンゾアズレン誘導体
JP2003506439A (ja) フルオレン誘導体
Schadt et al. Inhibitors of integrin α ν β 6
DE19912187A1 (de) Tetrahydrofuranderivate